alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Exhibit 4.2

Schedule 1 to Exhibit 4.1  Individual Deviations from Standard Management Board Services  Agreement by Current Members of Management Board

|Name                                    |  | For reporting
period |  | Term;
§1(i)              |  | Appointed by
Resolution of
Supervisory
Board dated; §1(i) |  | Fixed Annual
Salary;
§4(i)(a) |  | Bonus;
§4(i)(b) |  | Additional
bonus;
§4(i)(b) 2d.
par. |   | Position;
§1(i)
|--------------------------------------- |  | -------------------- |  | ------------------------ |  | --------------------------------------------------------- |  | ----------------------------- |  | --------------- |  | ----------------------------------- | - | ---------------
|Kai-Uwe Ricke                           |  | 1.1. to
31.12.2005   |  | 15.11.2002 to
14.11.2007 |  | Nov. 14, 2002                                             |  | 1,250,000                     |  | 1,250,000       |  | 20                                  | % | Chairman       
|Dr. Karl-Gerhard Eick                   |  | 1.1. to
31.12.2005   |  | 1.12.2002 to
30.11.2007  |  | Nov. 28, 2002                                             |  | 937,500                       |  | 937,500         |  | 20                                  | % | Vice-Chairman  
|Dr. Heinz Klinkhammer(1)                |  | 1.1. to
31.12.2005   |  | 1.4.2001 to
31.3.2006    |  | Apr. 13, 2000                                             |  | 750,000                       |  | 750,000         |  | 20                                  | % | Member         
|Rene Obermann                           |  | 1.1. to
31.12.2005   |  | 1.12.2002 to
30.11.2007  |  | Nov. 28, 2002                                             |  | 750,000                       |  | 750,000         |  | 20                                  | % | Member         
|Konrad F. Reiss (died on April 4, 2005) |  | 1.1. to
31.12.2005   |  | 20.1.2003 to
19.1.2008   |  | Jan. 16, 2003                                             |  | 750,000                       |  | 750,000         |  | 20                                  | % | Member         
|Lothar Pauly (2)                        |  | 1.1. to
31.12.2005   |  | 1.10.2005 to
30.9.2010   |  | Sept. 2, 2005                                             |  | 750,000                       |  | 750,000         |  | 20                                  | % | Member         
|Walter Raizner                          |  | 1.1. to
31.12.2005   |  | 1.11.2004 to
31.10.2009  |  | Sept. 3, 2004                                             |  | 937,500                       |  | 937,500         |  | 20                                  | % | Member         

---

---



QuickLinks
<PAGE>

                                                                    EXHIBIT 23.1

                        Consent of Independent Auditors
                        -------------------------------

Board of Directors
IAS Communications, Inc.


We consent to the use of our report dated July 15, 1999 on the financial
statements of IAS Communications, Inc. as of April 30, 1999 and 1998 that are
included in the Form 10-KSB, which is included, by reference in the Company's
Form S-8.

Dated this 30/th/ day of July, 1999
Vancouver, Canada

ELLIOTT TULK PRYCE ANDERSON
Chartered Accountants

/s/ Elliott Tulk Pryce Anderson
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Dental and Craniofacial Research Special Emphasis Panel; Review of R13 Application for NIH Support of Conferences and Scientific Meetings.                     

*Date:*                         March 26, 2010.                    

*Time:*                         1 p.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         National Institutes of Health, One Democracy Plaza, 6701 Democracy Boulevard, Bethesda, MD 20892 (Virtual Meeting).                    

*Contact Person:*                         Victor Henriquez, PhD, Scientific Review Officer, DEA/SRB/NIDCR, 6701 Democracy Blvd., Room 668, Bethesda, MD 20892-4878, 301-451-2405,                         *henriquv@nidcr.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.121, Oral Diseases and Disorders Research, National Institutes of Health, HHS)

Dated: February 19, 2010.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 2010-3918 Filed 2-25-10; 8:45 am]

BILLING CODE 4140-01-P
ARMED SERVICES BOARD OF CONTRACT APPEALS 

Appeal of--

McClain Contracting Company, Inc. 

Under Contract No. NNS15AA10C 

APPEARANCES FOR THE APPELLANT: 

) 

) 

) 

) 

) 

APPEARANCES FOR THE GOVERNMENT: 

ASBCA No. 61904 

Joseph R. Duncan, Jr., Esq. 

Jeremy Gaddy, Esq. 

Clark, May, Price, Lawley, Duncan & 

Paul, LLC 

Birmingham, AL 

Scott Barber, Esq. 

NASA Chief Trial Attorney 

Jeffrey A. Renshaw, Esq. 

Trial Attorney 

Stennis Space Center, MS 

ORDER OF DISMISSAL 

The dispute has been settled. The appeal is dismissed with prejudice. 

Dated: October 29, 2019 

ministrative Judge 

Chairman 

Armed Services Board 

of Contract Appeals 

I certify that the foregoing is a true copy of the Order of Dismissal of the Armed 

Services Board of Contract Appeals in ASBCA No. 61904, Appeal of McClain Contracting 

Company, Inc., rendered in conformance with the Board's Charter. 

Dated: 

PAULLA K. GATES-LEWIS 

Recorder, Armed Services 

Board of Contract Appeals
#### State of Connecticut *v.*Arthur Holliday State of Connecticut *v.*Albert Daniels

*Nathan Aaron,*in support of the motion.

Submitted March 26

decided April 3, 1969

The motion by the defendants for review of the trial court’s refusal to rectify the appeal from the Superior Court in Hartford County is denied.
##### 



TERMINATION OF SHAREHOLDERS AGREEMENT
RELATING TO VITRAN CORPORATION INC.

WHEREAS, the undersigned are all of the parties to a Shareholders
Agreement made as of the 15th day of July, 1987 with respect to Vitran
Corporation Inc.; and

WHEREAS, the undersigned wish to terminate the Shareholders Agreement
effective as of February 1, 2003.

NOW THEREFORE, THIS AGREEMENT WITNESSESthat for good and valuable
consideration, the parties hereto agree as follows:

1.     The Shareholders Agreement is hereby terminated effective as of February 1,
2003 and the parties are released from all obligations thereunder.

2.     This Agreement shall enure to the benefit of and be binding upon the parties
hereto and their respective heirs, executors, administrators, legal personal
representatives, successors and assigns.

3.     This Agreement may be executed in one or more counterparts, each of which
when executed by any party hereto shall be deemed to be an original of such
counterparts and together shall constitute one and the same instrument.

4.     This Agreement may also be executed by facsimile.

IN WITNESS WHEREOF, the parties have executed this Agreement as of
February 1, 2003.

| |  |                                       
| |  | --------------------------------------
| |  | LOCHAN ORA INVESTMENTS LIMITED        
| |  |                                       
| |  | /s/ Richard D. McGraw                 
| |  |                                       
| |  |                                       
| |  | PARKWAY AUTOMOTIVE INVESTMENTS LIMITED
| |  |                                       
| |  | /s/ Richard D. McGraw                 
| |  |                                       

1



---



##### 



| |  |                           
| |  | --------------------------
| |  | 442769 ONTARIO LIMITED    
| |  |                           
| |  | /s/ Anthony Griffiths     
| |  |                           
| |  |                           
| |  | ATL FINANCIAL SERVICES INC
| |  |                           
| |  | /s/ Albert Gnat           
| |  |                           

|               |  |                      
|-------------- |  | ---------------------
|/s/ P. Stuart  |  | /s/ Albert Gnat      
|               |  |                      
|Witness        |  | ALBERT GNAT          
|              
|/s/ G. McGraw  |  | /s/ Richard D. McGraw
|               |  |                      
|Witness        |  | RICHARD D. McGRAW    
|              
|/s/ Mary Keogh |  | /s/ Anthony Griffiths
|               |  |                      
|Witness        |  | ANTHONY F. GRIFFITHS 

2
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7720 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7720

 To permit the Byrne JAG grant to be used for the purchase of fentanyl 
                testing kits and opioid reversal agents.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             March 19, 2024

 Mr. Kean of New Jersey (for himself and Mr. Van Drew) introduced the 
  following bill; which was referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
 To permit the Byrne JAG grant to be used for the purchase of fentanyl 
                testing kits and opioid reversal agents.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Fight Against Fentanyl Act''.

SEC. 2. FENTANYL TESTING KITS AND OPIOID REVERSAL AGENTS.

    Section 501(a)(1)(E) of title I of the Omnibus Crime Control and 
Safe Streets Act of 1968 (34 U.S.C. 10152(a)(1)(E)) is amended by 
inserting ``, including programs to purchase fentanyl testing kits and 
opioid reversal agents'' before the period.
                                 <all>
```
§ 507.51 Modified requirements that apply to a facility solely engaged in the storage of unexposed packaged animal food. ( a ) If a facility that is solely engaged in the storage of unexposed packaged animal food stores any such refrigerated packaged animal food that requires time/temperature control to significantly minimize or prevent the growth of, or toxin formation by pathogens, the facility must conduct the following activities as appropriate to ensure the effectiveness of the temperature controls: ( 1 ) Establish and implement temperature controls adequate to significantly minimize or prevent the growth of, or toxin formation by, pathogens;
( 2 ) Monitor the temperature controls with adequate frequency to provide assurance that the temperature controls are consistently performed;
( 3 ) If there is a loss of temperature control that may impact the safety of such refrigerated packaged animal food, take appropriate corrective actions to: ( i ) Correct the problem and reduce the likelihood that the problem will recur;
( ii ) Evaluate all affected animal food for safety; and
( iii ) Prevent the animal food from entering commerce, if you cannot ensure the affected animal food is not adulterated under section 402 of the Federal Food, Drug, and Cosmetic Act;
( 4 ) Verify that temperature controls are consistently implemented by: ( i ) Calibrating temperature monitoring and recording devices (or checking them for accuracy);
( ii ) Reviewing records of calibration within a reasonable time after the records are created; and
( iii ) Reviewing records of monitoring and corrective actions taken to correct a problem with the control of temperature within 7-working days after the records are created or within a reasonable timeframe, provided that the preventive controls qualified individual prepares (or oversees the preparation of) a written justification for a timeframe that exceeds 7-working days; and
( 5 ) Establish and maintain the following records: ( i ) Records (whether affirmative records demonstrating temperature is controlled or exception records demonstrating loss of temperature control) documenting the monitoring of temperature controls for any such refrigerated packaged animal food;
( ii ) Records of corrective actions taken when there is a loss of temperature control that may impact the safety of any such refrigerated packaged animal food; and
( iii ) Records documenting the verification activities.
( b ) The records that a facility must establish and maintain under paragraph (a)(5) of this section are subject to the requirements of subpart F of this part.
[80 FR 56337, Sept. 17, 2015, as amended at 81 FR 3718, Jan. 22, 2016]
<PAGE>   1
                                                                      EXHIBIT 13

   INDEPENDENT PUBLIC ACCOUNTANTS' REVIEW REPORT


   To the Board of Directors and Shareholders of
   Essef Corporation
   Chardon, Ohio


   We have reviewed the accompanying condensed consolidated balance sheet of
   Essef Corporation and Subsidiaries (the "Company") as of December 31, 1997,
   and the related condensed consolidated statements of income and cash flows
   for the three-month periods ended December 31, 1997 and 1996. These financial
   statements are the responsibility of the Company's management.

   We conducted our reviews in accordance with standards established by the
   American Institute of Certified Public Accountants. A review of interim
   financial information consists principally of applying analytical procedures
   to financial data and making inquiries of persons responsible for financial
   and accounting matters. It is substantially less in scope than an audit
   conducted in accordance with generally accepted auditing standards, the
   objective of which is the expression of an opinion regarding the financial
   statements taken as a whole. Accordingly, we do not express such an opinion.

   Based on our reviews, we are not aware of any material modifications that
   should be made to such condensed consolidated financial statements for them
   to be in conformity with generally accepted accounting principles.

   We have previously audited, in accordance with generally accepted auditing
   standards, the consolidated balance sheet of the Company as of September 30,
   1997, and the related consolidated statements of income, shareholders'
   equity, and cash flows for the year then ended (not presented herein) and in
   our report dated November 19, 1997, we expressed an unqualified opinion on
   those consolidated financial statements. In our opinion, the information set
   forth in the accompanying condensed consolidated balance sheet as of
   September 30, 1997 is fairly stated, in all material respects, in relation to
   the consolidated balance sheet from which it has been derived.


   DELOITTE & TOUCHE LLP

   Cleveland, Ohio
   January 23, 1998

                                  Page 15 of 16
**Consent
      of Independent Auditors**









The
      Board
      of Directors


Preferred
      Voice, Inc.




We
      hereby
      consent to the use in the Form 10-KSB filing of our report dated July 9, 2007,
      relating to the balance sheet of Preferred
      Voice, Inc. as of March 31, 2007, and the related statements of operations,
      changes in shareholders' equity, and cash
      flows for the year ended March 31, 2007, which are contained in that
      filing.






**Philip
                Vogel & Co. PC**/s/ Philip Vogel & Co.
              PC






Dallas,
      Texas




July
      13, 2007
§ 640.102 Manufacture of Immune Globulin (Human). ( a ) *Processing method.* The processing method shall be one that has been shown: ( 1 ) To be capable of concentrating tenfold from source material at least two different antibodies;
( 2 ) not to affect the integrity of the globulins;
( 3 ) to consistently yield a product which is safe for subcutaneous and intramuscular injection and
( 4 ) not to transmit viral hepatitis.
( b ) *Microbial contamination.* Low temperatures or aseptic techniques shall be used to minimize contamination by microorganisms. Preservatives to inhibit growth of microorganisms shall not be used during processing.
( c ) *Bulk storage.* The globulin fraction may be stored in bulk prior to further processing provided it is stored in clearly identified hermetically closed vessels. Globulin as either a liquid concentrate or a solid and containing alcohol or more than 5 percent moisture shall be stored at a temperature of −10 °C or lower. Globulin as a solid free from alcohol and containing less than 5 percent moisture, shall be stored at a temperature of 0 °C or lower.
( d ) *Determination of the lot.* Each lot of Immune Globulin (Human) shall represent a pooling of approximately equal amounts of material from not less than 1,000 donors.
( e ) *Sterilization and heating.* The final product shall be sterilized promptly after solution. At no time during processing shall the product be exposed to temperatures above 45 °C, and after sterilization the product shall not be exposed to temperatures above 32 °C for more than 72 hours.
[38 FR 32089, Nov. 20, 1973, as amended at 50 FR 4140, Jan. 29, 1985; 63 FR 16685, Apr. 6, 1998; 64 FR 26287, May 14, 1999; 65 FR 13679, Mar. 14, 2000; 65 FR 52018, Aug. 28, 2000]
| (1)   | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------|

| (2)   | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | /s/Rick Etskovitz                                              |
|--------|----------------------------------------------------------------|
|   | Rick Etskovitz                                                 |
|   | Chief Financial Officer                                        |
|   | (Principal Financial Officer and Principal Accounting Officer) |
|   | March 24, 2011                                                 |
|   |                                                           |

----
118TH CONGRESS 

2D SESSION H. R. 7417 

AN ACT 

To designate the facility of the United States Postal Service 

located at 135 West Spring Street in Titusville, Pennsylvania, as the ‘‘Edwin L. Drake Post Office Building’’. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 
2 

•HR 7417 EH

1 SECTION 1. EDWIN L. DRAKE POST OFFICE BUILDING. 

2 (a) DESIGNATION.—The facility of the United States 

3 Postal Service located at 135 West Spring Street in 

4 Titusville, Pennsylvania, shall be known and designated 

5 as the ‘‘Edwin L. Drake Post Office Building’’. 

6 (b) REFERENCES.—Any reference in a law, map, reg7 ulation, document, paper, or other record of the United 

8 States to the facility referred to in subsection (a) shall 

9 be deemed to be a reference to the ‘‘Edwin L. Drake Post 

10 Office Building’’. 

Passed the House of Representatives June 3, 2024. 

Attest: 

Clerk. 

118TH CONGRESS 

2D SESSION H. R. 7417 

AN ACT 

To designate the facility of the United States PostPost Office Building’’. Titusville, Pennsylvania, as the ‘‘Edwin L. Drake al Service located at 135 West Spring Street in
EXHIBIT 5.1

                         OPINION AND CONSENT OF COUNSEL

December 19, 2001

Crown Jewel Resources, Corp.
805 Third Avenue
New York, New York 10022

Gentlemen:

      We have examined the Registration Statement on Form S-8 of Crown Jewel
Corp., a Delaware corporation (the "Registrant"), to be filed with the
Securities and Exchange Commission (the "Registration Statement"), relating to
the registration under the Securities Act of 1933, as amended, of 1,200,000
shares of the Company's common stock, $.0005 par value per share (the "Common
Stock"), under the Consulting Agreement dated December 1, 2001 between the
Registrant and Leon Odzer, the Consulting Agreement dated December 1, 2001
between the Registrant and Carmine Trinchetta and the Consulting Agreement dated
December 1, 2001 between the Registrant and Marcello Trento (collectively, the
"Consulting Agreements").

      As your counsel in connection with this transaction, we have examined the
proceedings taken and are familiar with the proceedings proposed to be taken by
you in connection with the issuance and sale of the Common Stock pursuant to the
Consulting Agreements.

      We are of the opinion that the shares of Common Stock, when issued and
sold in the manner described in the Registration Statement and the exhibits
thereto, will be legally and validly issued, fully-paid and non-assessable.

      We consent to the use of this opinion as an exhibit to the Registration
Statement and further consent to all references to us in the Registration
Statement.

Very truly yours,

/s/ KAPLAN GOTTBETTER & LEVENSON, LLP


                                      E-10
**EXHIBIT 32.1****CERTIFICATIONS**Each of the undersigned hereby certifies, in accordance with 18 U.S.C. 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, in his capacity as an officer of Vitran CorporationInc., that, to his knowledge, the Annual Report of Vitran Corporation Inc. on Form 10-K for theyear ended December 31, 2005, fully complies with the requirements of Section 13(a) of theSecurities Exchange Act of 1934 and that the information contained in such report fairly presents,in all material respects, the financial condition and results of operation of Vitran CorporationInc.       Date: February 8, 2006 By: /s/ RICHARD E. GAETZ       Richard E. Gaetz      President and      Chief Executive Officer           By: /s/ SEAN P. WASHCHUK       Sean P. Washchuk      Vice President Finance and